mefacap 250 capsule
mefanamic acid 250mg
mefacap 250 caps (pom)
mefenanic acid 250mg
mefacol(r) injection
chloramphenicol 1.0g
mefacol x 100's, 1000
chloramphenicol 250mg
mefacid 500mg capsule
rl pharma distributor - mefenamic acid - capsule - 500mg
mefacid tablets 250 mg
zafa pharmaceutical - tablets - mefenamic acid 250mg - anti-inflammatory / n.s.a.i.d
mefacid tablets 250 mg
zafa pharmaceutical - tablets - mefenamic acid 250mg - anti-inflammatory / n.s.a.i.d
gilenya 0.5 mg
novartis israel ltd - fingolimod as hydrochloride - hard capsule - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
gilenya
novartis new zealand ltd - fingolimod hydrochloride 0.56mg; ; ; - capsule - 0.5 mg - active: fingolimod hydrochloride 0.56mg excipient: capsugel white 4998 gelatin ink iron oxide yellow magnesium stearate mannitol titanium dioxide - gilenya is indicated as a disease modifying therapy for the treatment of patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
fingolimod sandoz fingolimod (as hydrochloride) 0.5 mg capsule blister pack
sandoz pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: mannitol; iron oxide yellow; magnesium stearate; gelatin; titanium dioxide - fingolimod sandoz is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.